Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial
Young-Il Jo, Ha-Young Na, Ju-Young Moon, Sang-Woong Han, Dong-Ho Yang, Sang-Ho Lee, Hyeong-Cheon Park, Hoon-Young Choi, So-Dug Lim, Jeong-Hae Kie, Yong-Kyu Lee, Sug-Kyun Shin
Korean J Intern Med. 2016;31(2):335-343.   Published online 2016 Feb 15     DOI: https://doi.org/10.3904/kjim.2014.266
Citations to this article as recorded by Crossref logo
Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway
Inho Kim, Chan Soon Park, Hae-Young Lee
Korean Circulation Journal.2019; 49(7): 615.     CrossRef
Flow Features of Immunoglobulin A Nephropathy Depending on Activity / Risk of Progression and Influence of Pathogenetic Therapy
Olga Nikolaevna Sigitova, Taisia Yurevna Kim, Alexandra Vladimirovna Salmakova
BioNanoScience.2019; 9(2): 495.     CrossRef
Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria
Liu Xiaowei, Wang Bo, Li Li, Zhang Peng
International Urology and Nephrology.2019;[Epub]     CrossRef
24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
Hae-Young Lee, Cheol-Ho Kim, Jae-Kwan Song, Shung Chull Chae, Myung Ho Jeong, Dong-Soo Kim, Byung-Hee Oh
The Korean Journal of Internal Medicine.2017; 32(6): 1025.     CrossRef
Modern classification, progression factors, treatment and outcomes of primary mesangial proliferative glomerulonephritis
O N Sigitova, T Yu Kim, R R Sharipova
Kazan medical journal.2017; 98(5): 784.     CrossRef